June 03, 2019
Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer
Media
June 03, 2019
Nordic Nanovector: European patent granted for Betalutin® or Humalutin® in combination with anti-CD20 antibodies for treating NHL
June 03, 2019
Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
June 03, 2019
Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)
May 29, 2019
Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude
May 23, 2019
Targovax to fully focus on ONCOS oncolytic virus program
May 23, 2019
Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
May 23, 2019
Nordic Nanovector ASA – Results for the First Quarter 2019
May 21, 2019
MIPS acquires patent rights and the brand FLUID
May 21, 2019
Nordic Nanovector: Archer-1 phase 1b Betalutin®/rituximab combination trial advances to next cohort
